by Richard Daverman, PhD
January 4, 2013 --After a 14-month hiatus, China’s IPO window will soon reopen under a new system of more market-oriented procedures, and three life science companies are among the initial 11 IPO candidates; Stellar Biotech of California received $12 million in capital from Amaran, a Taiwanese biotech, as part of a cancer immunotherapy collaboration; DIH Medical, a Beijing-based medical device distributor, gained China rights to market Zynex’s stroke recovery device; Chugai Pharma of Japan will take control of its own China marketing, investing $30 million in a China Medical City facility; China’s disease control agency found that Shenzhen Kangtai Biological’s hepatitis B vaccine did not cause the deaths of nine children; and the CFDA temporarily halted importation of Pfizer’s anti-fungal treatment Diflucan because of missing paperwork. More details….
Stock Symbols: (OTCQB: SBOTF; TSX: KLH) (OTCQB: ZYXI) (JP: 4519) (NYSE: PFE)
Help employers find you! Check out all the jobs and post your resume.
